# Pathalys Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathalys-pharma

- Industry: Biotechnology
- Headquarters: Raleigh, US
- Website: www.pathalys.com
- Total disclosed funding: $105M
- Latest round: Series B (Aug 6, 2024)
- Investors on record: 8

## About

Based in North Carolina, US, and founded in 2021, Pathalys Pharma, Inc. provides treatment for end-stage renal disease. As of 2024, the company is headed by its CEO Neal Fowler. 
In January 2023, the firm raised an amount of venture funding led by investor Abingworth, with participation from other investors Carlyle Group and OrbiMed Advisors. Returning investors Catalys Pacific and DaVita Venture Group also participated in the round. The round was part of a larger USD 150 million equity and debt financing.

The company offers solutions for patients with end-stage kidney disease. Pathalys provides calcimimetics for the treatment of SHPT. By activating the calcium-sensing receptor, which is expressed in a variety of human organ tissues, calcimimetic is a medication that simulates the effects of calcium on tissues.

## Funding rounds

- Series B, Aug 6, 2024, $105M — Marshall Wace, KB Investment, Japan Post Investment Corporation, Samsara BioCapital, Catalys Pacific, DaVita Venture Group, TCG Crossover Management, JP Morgan Life Sciences Private Capital
- Seed, Mar 1, 2022 — Catalys Pacific, DaVita Venture Group

## Investors

- Catalys Pacific (https://capitalatlas.ai/funds/catalys-pacific) — Seed, Series B
- DaVita Venture Group (https://capitalatlas.ai/funds/davita-venture-group) — Seed, Series B
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series B
- Japan Post Investment Corporation — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- JP Morgan Life Sciences Private Capital (https://capitalatlas.ai/funds/jp-morgan-life-sciences-private-capital) — Series B